← All trials
NCT02431663
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 1, 2015
- Primary completion
- Apr 1, 2016
- Completion date
- Apr 1, 2016
- First posted
- —
- Last posted
- —
- Enrollment
- 57
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Technion UniversityLead sponsor
- Nuovo Regina Margherita HospitalCollaborator
- Vittore Buzzi Children's HospitalCollaborator
- Marche Polytechnic UniversityCollaborator
- University of FlorenceStudy chair
- University of PadovaCollaborator
- Bambino Gesù Hospital and Research InstituteCollaborator
- University of BolognaCollaborator
- Catholic University of Sacred Heart, RomeCollaborator
- University of VeronaCollaborator
- University of TriesteCollaborator
- Technion UniversityReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.